BPGbio to Share Updates in Development of Late-Stage AI-Developed Therapeutic Pipeline at the Pharma Partnering Summit

BPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced plans to present on their groundbreaking AI-developed therapeutics portfolio at the upcoming Pharma Partnering Summit in Boston October 19-20, 2023. At the meeting, BPGbio's President and CEO, Dr. Niven R. Narain, and Executive Chairman Daniel Elliott will unveil the progress made in advancing their oncology drug candidate BPM31510, currently under investigation for glioblastoma multiforme (GBM) and pancreatic cancer. They will also provide insights into the company's growing portfolio of AI-discovered therapeutics and diagnostics, identified through the company's proprietary NAi Interrogative Biology® Platform.

"We are excited to share with industry peers, partners and the investment community about BPGbio's AI-driven late stage clinical assets at the Pharma Partnering Summit," said Niven R. Narain, Ph.D., President & CEO, BPGbio, Inc. "The positive progress we are making in our clinical trials continue to validate the efficacy of our AI powered NAi Interrogative Biology Platform, with our lead oncology candidatbusine, BPM31510, demonstrating an early indication for potential clinical benefit for both GBM and pancreatic cancer?two of the most aggressive and deadly cancers."

BPM31510, the company's lead drug candidate is a small molecule compound currently in a Phase 2b clinical trial led by Stanford for glioblastoma multiforme GBM. Notably, BPM31510 has also garnered a favorable recommendation from the medical advisory board to progress into Phase 2b trials for pancreatic cancer. BPM31510 acts by targeting the mitochondrial machinery and tumor microenvironment (TME) to create a metabolic shift in cancer cells, leading to cancer cell death.

In addition, BPGbio's therapeutic pipeline also includes drug candidates for Epidermolysis Bullosa (EB), Squamous Cell Carcinoma (SCC), Sarcopenia, solid and liquid tumors, Huntington's disease, and Parkinson's disease. The company's diagnostic pipeline includes its prostate cancer diagnostic test pstateDx, which is being launched in Mexico, as well as tests being developed and validated for the detection of Parkinson's disease (ParkinsonDx), pancreatic cancer (PancDx), breast cancer, and liver disease.

About BPGbio, Inc.

BPGbio is a leading AI-powered clinical stage biopharma and diagnostics company focused on oncology, neurology, and rare diseases. The company has a deep portfolio of AI-developed pipeline of therapeutics, including several in late-stage development. BPGBio's novel approach is underpinned by NAI, its proprietary Interrogative Biology Platform, protected by over 450 US and international patents; the world's largest clinically annotated non-governmental biobank; and exclusive access to the most powerful supercomputer in the world. With these tools, BPGbio is redefining how patient biology can be modeled using unbiased AI. Headquartered in Boston, the company is at the forefront of a new era in medicine, combining biology, data, and AI to transform the way we understand aging, human performance, and diagnose and treat disease. For more information, visit bpgbio.com.